Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
Identification of Selective Lead Compounds for Treatment of High-Ploidy Breast Cancer
ML-211 Catalog No.:M23412-C Identification of Selective Lead CompoundsIC50: LYPLA1 (17 nM) and the related LYPLA2 (30 nM) ML 211 is a dual inhibitor of LYPLA1 and the related LYPLA2. Lysophospholipase 1 (LYPLA1), a protein palmitoyl thioesterase, is responsible for depalmitoylation of the oncogene HRas. Palmitoylation of such oncogenes is considered to be required for trafficking and malignant transformation, making LYPLA1 a promising target for downregulating oncogenic signaling. In vitro: ML 211 was identified as a
US$ 29.00
US$ 29.00
US$ 29.00
US$ 17.25
US$ 17.25
US$ 27.00
US$ 27.00
US$ 21.75
US$ 27.00
US$ 24.00
US$ 29.00
US$ 18.00
US$ 29.00
US$ 27.00
US$ 1019.50
US$ 8391.50
US$ 1207.00
US$ 1089.50